tradingkey.logo

Guardant Health Inc

GH
View Detailed Chart
63.380USD
+0.540+0.86%
Close 10/06, 16:00ETQuotes delayed by 15 min
7.89BMarket Cap
LossP/E TTM

Guardant Health Inc

63.380
+0.540+0.86%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.86%

5 Days

+2.24%

1 Month

+5.40%

6 Months

+56.19%

Year to Date

+107.46%

1 Year

+186.01%

View Detailed Chart

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2025-10-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking
22 / 207
Overall Ranking
92 / 4706
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 26 analysts
Buy
Current Rating
66.022
Target Price
+5.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Guardant Health Inc Highlights

StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 64.39% year-on-year.
Undervalued
The company’s latest PE is -18.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 124.12M shares, decreasing 11.43% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 2.82M shares of this stock.

Financial Indicators

EPS

No Data

Total revenue

No Data

Guardant Health Inc Info

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Ticker SymbolGH
CompanyGuardant Health Inc
CEODr. Amirali Talasaz, Ph.D.
Websitehttps://guardanthealth.com/
KeyAI